Claudia Warden, Kayla Steed, Whitney Hotsinpiller, Joel Pogue, Joseph Harms, Michael Soike, Kimberly Keene, Michael Dobelbower, Markus Bredel, Dennis Stanley, D Hunter Boggs
{"title":"cbct引导的在线适应性放射治疗加速部分乳房照射：单一机构的经验。","authors":"Claudia Warden, Kayla Steed, Whitney Hotsinpiller, Joel Pogue, Joseph Harms, Michael Soike, Kimberly Keene, Michael Dobelbower, Markus Bredel, Dennis Stanley, D Hunter Boggs","doi":"10.1016/j.clbc.2025.08.018","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose/objectives: </strong>Accelerated partial breast irradiation (APBI) using stereotactic body radiation therapy (SBRT) offers shorter treatment, comparable local control, and improved cosmesis for early-stage breast cancer (ESBC). Cone beam CT (CBCT)-guided online adaptive radiation therapy (OART) enhances target coverage and minimizes normal tissue exposure. This retrospective study evaluates clinical characteristics and outcomes in patients treated with APBI using OART.</p><p><strong>Materials/methods: </strong>From January 2022 to May 2024, 40 patients (including 2 with bilateral disease) received SBRT with OART. Targets included the lumpectomy cavity (GTV), a 1 cm CTV margin, and a 3 mm PTV margin. Patients received 30 Gy in 5 fractions. Daily CBCT guided alignment and adaption of targets and organs-at-risk was performed. Either the scheduled or adapted plan was selected each day. Outcomes were assessed at 1 month and most recent follow-up using CTCAE criteria.</p><p><strong>Results: </strong>Patients (ages 50-83) had predominantly right-sided (59.5%) and upper outer quadrant tumors (61.9%), with a median size of 0.9 cm. The median interval from lumpectomy to radiation was 62 days; treatment lasted a median of 9 days. The adapted plan was used in 90% of fractions. At 1 month, 48% had no toxicity; all reported events were grade 1. At a median 14.3-month follow-up, most toxicities remained grade 1; 3 patients had grade 2 effects. No recurrences were observed.</p><p><strong>Conclusions: </strong>This study, the largest APBI with OART cohort to date, demonstrates excellent cosmesis, minimal toxicity, and promising early oncologic outcomes for ESBC patients.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CBCT-Guided Online Adaptive Radiation Therapy for Accelerated Partial Breast Irradiation: A Single-Institution Experience.\",\"authors\":\"Claudia Warden, Kayla Steed, Whitney Hotsinpiller, Joel Pogue, Joseph Harms, Michael Soike, Kimberly Keene, Michael Dobelbower, Markus Bredel, Dennis Stanley, D Hunter Boggs\",\"doi\":\"10.1016/j.clbc.2025.08.018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose/objectives: </strong>Accelerated partial breast irradiation (APBI) using stereotactic body radiation therapy (SBRT) offers shorter treatment, comparable local control, and improved cosmesis for early-stage breast cancer (ESBC). Cone beam CT (CBCT)-guided online adaptive radiation therapy (OART) enhances target coverage and minimizes normal tissue exposure. This retrospective study evaluates clinical characteristics and outcomes in patients treated with APBI using OART.</p><p><strong>Materials/methods: </strong>From January 2022 to May 2024, 40 patients (including 2 with bilateral disease) received SBRT with OART. Targets included the lumpectomy cavity (GTV), a 1 cm CTV margin, and a 3 mm PTV margin. Patients received 30 Gy in 5 fractions. Daily CBCT guided alignment and adaption of targets and organs-at-risk was performed. Either the scheduled or adapted plan was selected each day. Outcomes were assessed at 1 month and most recent follow-up using CTCAE criteria.</p><p><strong>Results: </strong>Patients (ages 50-83) had predominantly right-sided (59.5%) and upper outer quadrant tumors (61.9%), with a median size of 0.9 cm. The median interval from lumpectomy to radiation was 62 days; treatment lasted a median of 9 days. The adapted plan was used in 90% of fractions. At 1 month, 48% had no toxicity; all reported events were grade 1. At a median 14.3-month follow-up, most toxicities remained grade 1; 3 patients had grade 2 effects. No recurrences were observed.</p><p><strong>Conclusions: </strong>This study, the largest APBI with OART cohort to date, demonstrates excellent cosmesis, minimal toxicity, and promising early oncologic outcomes for ESBC patients.</p>\",\"PeriodicalId\":10197,\"journal\":{\"name\":\"Clinical breast cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical breast cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clbc.2025.08.018\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.08.018","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
CBCT-Guided Online Adaptive Radiation Therapy for Accelerated Partial Breast Irradiation: A Single-Institution Experience.
Purpose/objectives: Accelerated partial breast irradiation (APBI) using stereotactic body radiation therapy (SBRT) offers shorter treatment, comparable local control, and improved cosmesis for early-stage breast cancer (ESBC). Cone beam CT (CBCT)-guided online adaptive radiation therapy (OART) enhances target coverage and minimizes normal tissue exposure. This retrospective study evaluates clinical characteristics and outcomes in patients treated with APBI using OART.
Materials/methods: From January 2022 to May 2024, 40 patients (including 2 with bilateral disease) received SBRT with OART. Targets included the lumpectomy cavity (GTV), a 1 cm CTV margin, and a 3 mm PTV margin. Patients received 30 Gy in 5 fractions. Daily CBCT guided alignment and adaption of targets and organs-at-risk was performed. Either the scheduled or adapted plan was selected each day. Outcomes were assessed at 1 month and most recent follow-up using CTCAE criteria.
Results: Patients (ages 50-83) had predominantly right-sided (59.5%) and upper outer quadrant tumors (61.9%), with a median size of 0.9 cm. The median interval from lumpectomy to radiation was 62 days; treatment lasted a median of 9 days. The adapted plan was used in 90% of fractions. At 1 month, 48% had no toxicity; all reported events were grade 1. At a median 14.3-month follow-up, most toxicities remained grade 1; 3 patients had grade 2 effects. No recurrences were observed.
Conclusions: This study, the largest APBI with OART cohort to date, demonstrates excellent cosmesis, minimal toxicity, and promising early oncologic outcomes for ESBC patients.
期刊介绍：
Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
